Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro

Pharmacology and Toxicology

Volumn 83, Issue 3, 1998, Pages 125-131

  Ylitalo, Ritva ^a   Kalliovalkama, Jarkko ^a   Wu, Xiumin ^a   Kankaanranta, Hannu ^a   Salenius, Juha Pekka ^b   Sisto, Tero ^b   Lähteenmäki, Tuula ^c   Ylitalo, Pauli ^a   Pörsti, Ilkka ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID;

ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL FUNCTION; CALCIUM CELL LEVEL; DRUG ACCUMULATION; DRUG EFFECT; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IN VITRO STUDY; INTERNAL MAMMARY ARTERY; MEMBRANE BINDING; MEMBRANE DEPOLARIZATION; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0031690322     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01455.x     Document Type: Article

References (40)

1. Amin, D., S. A. Cornell, M. H. Perrone & G. E. Bilder: 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res. 1996, 46, 759-762.
2. Amin, D., S. A. Cornell, S. K. Gustafson, S. J. Needle, J. W. Ullrich, G. E. Bilder & M. H. Perrone: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 1992, 33, 1657-1663.
3. Fast, D. K., R. Felix, C. Dowse, W. F. Neuman & H. Fleisch: The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem. J. 1978, 172, 97-107.
4. Felix, R., H. L. Guenther & H. Fleisch: The subcellular distribution of [14]dichloromethylene-bisphosphonate and [14]1-hydroxy-1,1-ethylidenebisphosphonate in cultured calvaria cells. Calcif. Tiss. Int. 1984, 36, 108-113.
5. Fitton, A. & D. McTavish: Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone diseases. Drugs 1991, 41, 289-318.
6. Fleisch, H., R. G. G. Russell, S. Bisaz, R. G. Muhlbauer & D. A. Williams: The inhibitory effect of bisphosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest. 1970, 1, 12-18.
7. Fleisch, H.: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42, 919-944.
8. Fleisch, H.: Bisphosphonates: A new class of drugs in diseases of hone and calcium metabolism. Handbook of Experimental Pharmacology 1988, 83, 441-466.
9. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.
10. Hanhijärvi, H., I. Elomaa, M. Karlsson & L. Lauren: Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int. J. Clin. Pharmacol. Therap. 1989, 27, 602-606.
11. Hollander, W., J. Paddock, S. Nagraj, M. Colombo & B. Kirkpatrick: Effects of anticalcifying and antifibrotic drugs on pre-established atherosclerosis in rabbit. Atherosclerosis 1979, 33, 111-123.
12. Johansen, T., T. Knudsen & H. Bertelsen: Reversal by EGTA of the enhanced secretory responsiveness of mast cells due to treatment with ouabain. FEBS Lett. 1990, 262, 228-230.
13. Kankaanranta, H. & E. Moilanen: Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. Mol. Pharmacol. 1995, 47, 1006-1013.
14. Kitamura, K. & H. Kuriyama: Molecular mechanisms of action of antihypertensive agents Ca-antagonists and K-channel openers on vascular smooth muscle. Handbook of Experimental Pharmacology 1994, 111, 595-630.
15. Kramsch, D. M. & C. T. Chan: The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrousfatty plaques in rabbits. Circ. Res. 1978, 42, 562-572.
16. Kramsch, D. M., A. J. Aspen & L. J. Rozter: Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 1981, 213, 1511-1513.
17. Kähönen, M., P. Arvola, X. Wu & I. Pörsti:. Arterial contractions induced by cumulative addition of calcium in hypertensive and normotensive rats: influence of endothelium. Naynyn-Schmiedeber's Arch. Pharmacol. 1994, 349, 627-636.
18. Lee, W. M. & K. T. Lee: Lack of effect of phenformin, pyridinolcarbamate combined with a decalcifying agent, and a onion-garlic mixture on growth and necrosis of aortic atherosclerosis in ballooned swine. Exp. Mol. Pathol. 1980, 33, 345-348.
19. 2+ channels. Mol. Pharmacol. 1992, 42, 489-498.
20. Liberman, U. A., S. R. Weiss, J. Bröll, H. W. Minne, H. Quan, N. H. Bell, J. Rodriguez-Portales, R. W. Downs Jr., J. Dequeker, M. Favus, E. Seeman, R. R. Recker, T. Capizzi, A. C. Santora II, A. Lombardi, R. V. Shah, L. J. Hirsch & D. B. Karpf: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl. J. Med. 1995, 333, 1437-1443.
21. Luckman, S. P., D. E. Hughes, F. P. Coxon, R. G. G. Russell & M. J. Rogers: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13, 581-589.
22. Marks, P. W. & F. R. Maxfield: Preparation of solutions with free calcium concentration in the nanomolar range using 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid. Anal. Biochem. 1991, 193, 61-71.
23. McCann, D. S., A. Koen, G. Zdybek & A. J. Boyk: Effect of chelation on phosphorus metabolism in experimental atherosclerosis. Circ. Res. 1962, 11, 880-984.
24. Mönkkönen, J., A. Urtti, P. Paronen, H. A. Elo & P. Ylitalo: The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro. Drug Metab. Dispos. 1989, 17, 690-693.
25. Paspaliaris, V. & D. D. Leaver: Clodronate inhibits contraction and prevents the action of L-type calcium channel antagonists in vascular smooth muscle. J. Bone Res. 1991, 6, 835-841.
26. Recker, R. R. & P. D. Saville: Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol. Appl. Pharmacol. 1973, 24, 580-589.
27. Rogers, M. J., X. Xiong, X. Ji, J. Mönkkönen, R. G. G. Russell, M. P. Williamson, F. H. Ebetino & D. J. Watts: Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm. Res. 1997, 14, 625-630.
28. Rosenblum, I. Y., L. Flora & R. Eisenstein: The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis. Atherosclerosis 1975, 22, 411-424.
29. Ross, R.: The pathogenesis of atherosclerosis - an update. Nature 1993, 362, 801-809.
30. Ross, R.: The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibres. J. Cell Biol. 1971, 50, 172-186.
31. Rossiert, J. R., J. A. Cox, E. J. Niesor & C. L. Bentzen: A new class of calcium entry blockers defined by 1,3-diphosphonates. J. Biol. Chem. 1989, 264, 16598-16607.
32. Rüegg, U. T., A. Wallnöfer, S. Weir & C. Cauvin: Receptor-operated calcium-permeable channels in vascular smooth muscle. J. Cardiovasc. Pharmacol. 1989, 14 (Suppl. 6), S49-58.
33. Sato, M., W. Grasser, N. Endo, R. Akins, H. Simmons, D. D. Thompson, E. Golub & A. Rodan: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991, 88, 2095-2105.
34. Schmidt, A., S. J. Rutledge, N. Endo, E. E. Opas, H. Tanaka, G. Wesolowski, C. T. Leu, Z. Huang, C. Ramachandaran, S. B. Rodan & G. A. Rodan: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3068-3073.
35. Tomita, T. & S. Iino: Ionic channels in smooth muscle. Handbook of Experimental Pharmacology 1994, 111, 35-56.
36. 2+ influx defect in frog peptic cells isolated with EGTA. Amer. J. Physiol. 1990, 258, G542-551.?
37. Wartman, A., T. L. Lampe, D. S. McCann & A. J. Boyle: Plaque reversal with MgEDTA in experimental atherosclerosis: Elastin and collagen metabolism. J. Atherosc. Res. 1967, 7, 331-341.
38. Ylitalo, R., J. Mönkkönen & S. Ylä-Herttuala: Effects of liposome-encapsulated bisphosphonates on the acetylated LDL metabolism and the viability of phagocyting cells. Life Sci. 1997, 62, 413-422.
39. Ylitalo, R., J. Mönkkönen, A. Urtti & P. Ylitalo: Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J. Lab. Clin. Med. 1996, 127, 200-206.
40. Ylitalo, R., O. Oksala, S. Ylä-Herttuala & P. Ylitalo: Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J. Lab. Clin. Med. 1994, 123, 769-776.